8-K: ASP Isotopes Secures Multi-Year Gadolinium-160 Supply Deal with Isotopia, Bolstering Cancer Therapy Production

ASP Isotopes Inc. announced a four-year supply agreement with Isotopia Molecular Imaging Ltd. for enriched Gadolinium-160, a critical precursor for advanced cancer therapies, alongside plans for an investor access event in South Africa.

Summary

• ASP Isotopes Inc. has entered into a four-year supply agreement with Isotopia Molecular Imaging Ltd. for enriched Gadolinium-160 (Gd-160), a crucial isotope for producing Terbium-161 (Tb-161) used in targeted radiotherapies.
• The agreement, commencing in 2026, has an expected minimum contract value of $1 million per annum.
• This partnership aims to resolve long-standing supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for various cancers, including prostate cancer and neuroendocrine tumors.
• ASP Isotopes will utilize its proprietary Quantum Enrichment technology for Gd-160 production, which will be part of a larger Quantum plant currently being designed and constructed.
• The company also announced an Investor Access Event in South Africa from June 16-18, 2025, offering investors tours of facilities and discussions on future plans.

Sentiment

Score: 8

Explanation: The document announces a significant new supply agreement with a recurring revenue component, addressing a critical industry need. It also highlights the company's technological advancements and proactive investor engagement, indicating strong positive momentum and future potential. The risks mentioned are standard forward-looking disclaimers and not new, immediate threats.

Positives

• Secured a significant four-year supply agreement for enriched Gadolinium-160 with Isotopia Molecular Imaging Ltd., ensuring a stable revenue stream.
• The contract has an expected minimum value of $1 million per annum, commencing in 2026, providing financial predictability.
• The agreement addresses a critical supply bottleneck for Terbium-161, an emerging medical isotope with high potential in targeted radiotherapies for cancer.
• Leverages ASP Isotopes' proprietary Quantum Enrichment technology, validating its advanced capabilities in isotope production.
• Positions ASP Isotopes at the forefront of the surging radiopharmaceutical market, expanding its influence in advanced cancer treatment.
• The company expects to sign additional Gd-160 orders during 2025, indicating further growth potential.
• Hosting an Investor Access Event in South Africa demonstrates transparency and provides stakeholders with direct insight into the company's progress and facilities.
• The company has already achieved commercial enrichment of Carbon-14 and Silicon-28, with Ytterbium-176 producing commercial samples, showcasing operational progress.

Risks

• Failure to obtain necessary regulatory and shareholder approvals for the proposed acquisition of Renergen.
• Potential disruption from the proposed acquisition of Renergen, making it more difficult to maintain business and operational relationships.
• Significant transaction costs and unknown liabilities related to the proposed acquisition of Renergen.
• Litigation or regulatory actions related to the proposed acquisition of Renergen.
• Uncertainty regarding the outcomes of various strategies and projects undertaken by the Company.
• Potential impact of laws or government regulations or policies in South Africa, the United Kingdom, or elsewhere.
• Reliance on the efforts of third parties for various aspects of operations.
• Ability to complete the construction and commissioning of enrichment plant(s) or to commercialize isotopes using the ASP technology or the Quantum Enrichment Process.
• Ability to obtain regulatory approvals for the production and distribution of isotopes.
• Uncertainty regarding the financial terms of any current and future commercial arrangements.
• Ability to complete certain transactions and realize anticipated benefits from acquisitions and contracts.
• Dependence on the Company's Intellectual Property (IP) rights and certain IP rights of third parties.
• The competitive nature of the isotope production industry.

Future Outlook

ASP Isotopes anticipates the commencement of its four-year Gadolinium-160 supply agreement with Isotopia in 2026, with an expected minimum annual value of $1 million. The company is in the process of designing and constructing a large Quantum plant, which will include the Gd-160 enrichment facility, and expects to secure additional Gd-160 orders in 2025. This strategic partnership is poised to expand treatment options for cancer patients globally, reinforcing ASP Isotopes' position in the radiopharmaceutical market. Future plans and strategies for 2025/2026 will be further detailed at the upcoming investor event.

Management Comments

• "By supplying Gd-160, we are eliminating a major bottleneck in the development of Tb-161 therapies. Our investment in enrichment technology positions us to support the radiopharmaceutical industry's growing demand for stable isotopes. This partnership accelerates the path to clinical adoption of Tb-161, which could redefine cancer treatment paradigms." Paul Mann, CEO of ASP Isotopes.
• "Tb-161's dual mechanism of action, including Auger electron emissions, enables precise targeting of micro-metastases while minimizing damage to healthy tissues. This partnership ensures a reliable Gd-160 supply chain, allowing us to scale production and advance our Tb-161-labeled drug candidates toward commercialization. We produce in our site in Israel and shortly the production will start in our second site in Indianapolis in the US." Dr. Eli Shalom, CEO of Isotopia.

Industry Context

The announcement comes amidst a surging global interest in radiopharmaceuticals, which deliver localized radiation therapy via tumor-seeking molecules. The partnership between ASP Isotopes and Isotopia directly addresses a critical supply chain challenge for Terbium-161 (Tb-161), an emerging medical isotope. Tb-161's dual mechanism of action, including Auger electron emissions, positions it as a potentially superior alternative to existing therapies like Lutetium-177 (Lu-177) and alpha-emitting isotopes, aligning with the oncology field's shift towards more precise and effective targeted radiotherapeutics.

Comparison to Industry Standards

• Isotopia has consistently manufactured Lutetium-177 (Lu-177) and maintained weekly Terbium-161 (Tb-161) production for its clinical trials over the past two years, demonstrating established capabilities in medical isotope production.
• Terbium-161 (Tb-161) is highlighted for its potential advantages over Lutetium-177 (Lu-177) and alpha-emitting isotopes due to its dual mechanism of action, including Auger electron emissions, which induce double-strand DNA breaks in cancer cells for more precise targeting and reduced damage to healthy tissues.

Stakeholder Impact

• Shareholders: Potential for increased revenue, market validation, and enhanced investor confidence due to a new supply agreement and transparent investor engagement.
• Customers (Isotopia Molecular Imaging Ltd.): Ensured reliable supply of critical precursor isotope (Gd-160), enabling scaling of Tb-161 production and advancement of drug candidates.
• Cancer Patients: Potential for expanded and more effective targeted radiotherapeutic treatment options through accelerated development of Tb-161 therapies.
• Radiopharmaceutical Industry: Addresses a significant supply bottleneck for a key medical isotope, supporting broader industry growth and innovation.

Next Steps

• Commencement of Gadolinium-160 supply to Isotopia in 2026.
• Continued design and construction of a large Quantum enrichment plant.
• Signing of additional Gadolinium-160 orders during 2025.
• Hosting the Investor Access Event in South Africa from June 16-18, 2025, with an optional visit to the Renergen Virginia Gas Project on June 19, 2025.
• Scaling Terbium-161 production and advancing Tb-161-labeled drug candidates toward commercialization by Isotopia.

Key Dates

Recommendation

Keywords

ASP Isotopes, Isotopia Molecular Imaging, Gadolinium-160, Terbium-161, Radiopharmaceuticals, Medical Isotopes, Cancer Therapies, Quantum Enrichment, Isotope Production, Advanced Materials, SEC Filing, Supply Agreement, Investor Event, South Africa, ASPI, Nuclear Medicine